Multiple sclerosis as an immune condition: the other side of the cannabis story

Multiple sclerosis: symptoms and disease activity are different questions

Cannabinoids have been studied for spasticity and other symptoms of multiple sclerosis (MS). This article instead focuses on a separate question: can cannabinoid pathways change the immune process that damages central nervous-system tissue? That distinction matters, because feeling less stiffness is not the same as preventing attacks, lesions or disability progression.

How immune cells enter the nervous system

MS involves immune-mediated injury to myelin and associated neural structures. Inflammatory T-cell pathways, including Th1 and Th17 responses, can contribute to damage; B cells and other immune-cell populations also matter. Immune activity interacts with the blood–brain barrier, microglia and local inflammatory mediators. Modern disease-modifying treatments are designed to affect parts of this disease process.

Why CB2 attracts interest

The endocannabinoid system crosses the boundary between immune and neural signaling. CB1 is prominent in many neural pathways, whereas CB2 has important roles in immune cells and can be expressed in activated microglia. In experimental settings, targeting these pathways can change inflammatory cytokines and immune-cell behavior.

Experimental autoimmune encephalomyelitis: useful but limited

EAE is a commonly used animal model of immune-driven central nervous-system inflammation. Certain cannabinoid manipulations have reduced inflammatory markers or disease-like signs in some EAE experiments. Animal models allow researchers to test mechanisms; they cannot reproduce all the complexity, treatment history or years-long progression of human MS.

The CUPID trial tested progression in people

A major randomized, placebo-controlled study discussed in the Hebrew source followed nearly 500 people with progressive MS, comparing medicinal dronabinol (Δ9-THC) with placebo over up to three years. It did not demonstrate a significant slowing of disability progression on its main outcome measures, including progression on the Expanded Disability Status Scale (EDSS). Brain MRI measures, including atrophy and lesion outcomes, also did not show a convincing disease-modifying advantage.

How can spasticity improve while MS still progresses?

A substance may modulate nerve signaling, reduce spasms or alter pain without preventing immune-mediated myelin injury. This is not a contradiction. It is the essential difference between symptomatic treatment and disease-modifying treatment. Evidence for some cannabinoid approaches to spasticity is stronger than evidence that they change the course of MS itself.

CBD and immune pathways

CBD affects several signaling mechanisms that do not amount to THC-like activation of CB1. Preclinical studies have explored changes in cytokines, Th1/Th17 responses and neuroinflammatory processes. Those results do not establish that CBD prevents relapses or slows disability in humans with MS.

Microglia and the idea of remyelination

Microglia are resident immune cells within the central nervous system. CB2 signaling in activated microglia is being studied as a possible way to alter detrimental inflammation. Researchers also investigate whether cannabinoid pathways can influence processes relevant to remyelination in models. There is currently no clinical proof in the source that consuming cannabis restores myelin lost to MS.

Do not confuse cannabis with approved disease-modifying therapies

Established MS medicines have been evaluated in large clinical programs and can reduce relapses, MRI lesions or other progression-related outcomes in eligible patients. Cannabis products do not have equivalent evidence to replace them. Changes to these treatments require guidance from the patient's neurology team.

Bottom line

The ECS connects nervous-system function and immunity and remains a valuable research target. For patients today, cannabinoid interventions may have a role in selected symptoms under professional oversight. They should not be presented as proven treatments for preventing MS progression, reducing relapses or restoring damaged myelin.

Read original Hebrew article ↗

Scientific sources cited by the Hebrew original

1. Zajicek J, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurology. Read source ↗
2. Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice. Read source ↗
3. Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. Read source ↗
4. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. 2026. Read source ↗